Fort Lauderdale, FL. - OmniComm Systems, Inc., a global leading provider of clinical data management technology, today announced that a global top 15 pharmaceutical organization selected TrialOne to automate its entire Phase I and BA/ BE clinic. The expressed aims are to standardize processes, improve business intelligence, ensure compliance, and achieve overall business transformation within its early phase research. TrialOne is a browser-based bedside data collection technology specifically designed to automate the workflows and processes within early phase research clinics. TrialOne is the market leading eSource system for early phase research clinics that addresses the following needs of this pharmaceutical organization:
TrialOne enables the automation of clinic data collection; standardizes recruiting; facilitates the collection of study data and sample tracking; reduces discrepancies inherent in paper-based applications; and ensures compliance. “With this key additional TrialOne success, OmniComm continues to reinforce its position as the market leader in early phase clinic automation,” said Kuno van der Post, SVP of business development, OmniComm Systems. “The close interaction with our major pharmaceutical and clinical research organization (CRO) clients has driven our solution to the point that one of the key reasons we were selected was in no small part due to references from our installed user base.”
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,800 clinical trials. For more information, visit
www.omnicomm.com
.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.